Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma

Summary

The purpose of this study is to compare once and twice daily GW685698 in asthma

Timeline

Start

2008-10

Primary completion

2009-03

Completion

2009-03

Outcome

Met primary endpoint

registry analysis (superiority or other test); Placebo vs FF 200 µg OD; p <0.001; Mean Difference (Final Values) 0.108 (95% CI 0.064 to 0.153); ANCOVA NCT00766090 ↗

registry analysis (superiority or other test); Placebo vs FF 100 µg BID; p <0.001; Mean Difference (Final Values) 0.098 (95% CI 0.054 to 0.142); ANCOVA NCT00766090 ↗

Publications

• Background Woodcock A, Bleecker ER, Busse WW, Lotvall J, Snowise NG, Frith L, Jacques L, Haumann B, Bateman ED. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res. 2011 Dec 21;12(1):160. doi: 10.1186/1465-9921-12-160.
• O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fluticasone Furoate	Other / unclassified	100 ug	Inhaled
Subject	Fluticasone Furoate	Other / unclassified	200 ug	Inhaled

Indications